RxDoctor Payments Data

Phuong Vo

Hematology & Oncology · Seattle, WANPI 1033478490

Payments from drug & device makers

$138,827in general payments, 2019–2025

Across 4 payments — averaging $34,707 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medexus Pharma, Inc.$139K
  • AstraZeneca$150
  • Incyte Corporation$125

What the payments were for

  • Speaking & faculty fees$15055%
  • Food & beverage$12545%

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medexus Pharma, Inc.2$138,552
AstraZeneca1$150
Incyte Corporation1$125

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,827 in reported general payments places this provider in the 65th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Medicare billing

Part B allowed, 2024
$19,100
Medicare patients
44
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →